secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001104659-25-017438
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Theravance Biopharma reports record Q4 and full year 2024 financial results with YUPELRI and TRELEGY milestones
--------------------------------------------------------------------------------

- YUPELRI US net sales reached $66.7M in Q4 2024 and $238.6M for full year, up 10% and 8% year-over-year, driven by increased customer demand.
- TRELEGY global net sales of $3.46B in FY 2024 triggered a $50M milestone from Royalty Pharma, received in February 2025.
- Company ended Q4 2024 with $88M cash, and CYPRESS study on track to enroll final patient by mid-2025.
- Q4 2024 total revenue was $18.8M from Viatris collaboration, with net loss of $15.5M and non-GAAP net loss of $2.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925017438/0001104659-25-017438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465925017438/tm257513d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-017438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer